Sym-023
- Generic Name
- Sym-023
Novartis Discontinues Phase 3 Trial of Sabatolimab for Myelodysplastic Syndromes
Novartis has halted the phase 3 STIMULUS-MDS2 trial of sabatolimab, a Tim3-targeting drug, for treating myelodysplastic syndromes (MDS) due to not meeting its primary endpoint. The decision reflects a strategic shift to prioritize other projects within Novartis' portfolio. This development marks a significant setback in the race to bring a Tim3-targeting therapy to market, amidst broader challenges in the field.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath